Sun's generic Razadyne ER granted regulatory approval

MUMBAI, India — The Food and Drug Administration has approved a generic Alzheimer’s disease treatment from Sun Pharmaceutical Industries.

Sun said Thursday that the FDA had approved its galantamine hydrobromide extended-release capsules in the 8-mg, 16-mg and 24-mg strengths.

The drug is a generic version of Johnson & Johnson’s Razadyne ER, which has annual sales of about $50 million, according to Sun.